1-[(1R)-3-氯-1-苯基丙基]吲哚 | 915954-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-[(1R)-3-氯-1-苯基丙基]吲哚
• 英文名称: 1-[(1R)-3-chloro-1-phenyl-1-propyl]-1H-indole
• 英文别名: (R)-1-(3-chloro-1-phenylpropyl)-1H-indole；1-[(1R)-3-Chloro-1-phenylpropyl]-1H-indole；1-[(1R)-3-chloro-1-phenylpropyl]indole
• CAS: 915954-09-5
• 化学式: C₁₇H₁₆ClN
• 分子量: 269.774
• InChiKey: GWJGECXRLOKBAW-QGZVFWFLSA-N

物化性质

• 沸点：
  432.8±38.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-[(1R)-3-氯-1-苯基丙基]吲哚 、 甲胺 以 乙醇 为溶剂， 反应 3.0h， 以75%的产率得到(R)-3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine
  参考文献：
  名称：

  Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines

  摘要：

  Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanarnine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.039
• 作为产物：
  描述：

  在 manganese(IV) oxide 、 三乙胺 作用下， 以 乙醚 、 1,2-二氯乙烷 为溶剂， 反应 48.5h， 生成 1-[(1R)-3-氯-1-苯基丙基]吲哚
  参考文献：
  名称：

  Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines

  摘要：

  Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanarnine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.08.039

文献信息

• Iridium-Catalyzed Regio- and Enantioselective N-Allylation of Indoles
  作者：Levi M. Stanley、John F. Hartwig

  DOI：10.1002/anie.200904338

  日期：2009.10.5
• Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines
  作者：Paige E. Mahaney、An T. Vu、Casey C. McComas、Puwen Zhang、Lisa M. Nogle、William L. Watts、Ani Sarkahian、Liza Leventhal、Nicole R. Sullivan、Albert J. Uveges、Eugene J. Trybulski

  DOI：10.1016/j.bmc.2006.08.039

  日期：2006.12

  Compounds with a combination of norepinephrine and serotonin reuptake inhibition have been approved in the US and Europe for a number of indications, including major depressive disorder and pain disorders such as diabetic neuropathy and fibromyalgia. Efforts to design selective norepinephrine reuptake inhibitors based on SAR from the aryloxypropanarnine series of monoamine reuptake inhibitors have led to the identification of a potent new class of dual acting norepinephrine and serotonin reuptake inhibitors, namely the 3-(1H-indol-1-yl)-3-arylpropan-1-amines. (c) 2006 Elsevier Ltd. All rights reserved.